Methotrexate treatment of ectopic pregnancy with mifepristone analysis of 38 cases.doc

 PAGE \* MERGEFORMAT 2 Methotrexate treatment of ectopic pregnancy with mifepristone analysis of 38 cases [Abstract] Objective: To evaluate the intravenous administration of methotrexate treatment of ectopic pregnancy with mifepristone in the effect. Methods: The cases of 38 cases. Routine and medication before the blood biochemical examination, no abnormality after 5% saline methotrexate 75 mg, intravenous infusion, 150 mg mifepristone fasting Burton clothing, while providing symptomatic treatment, 1 week after re-give 5% Saline Methotrexate 75 ~ 100 mg intravenous drip, close observation during treatment of abdominal pain, vaginal bleeding, and changes in vital signs. And review of blood, urine HCG. According to β  HCG blood and urine HCG results, if necessary, repeated administration of a second. Results: The intravenous administration of methotrexate treatment of ectopic pregnancy with mifepristone in the success rate of 78%. So that 78% of the patients from the pain of surgery. Conclusion: The intravenous administration of methotrexate treatment of ectopic pregnancy with mifepristone high success rate. [Keywords:] ectopic pregnancy; methotrexate; intravenous injection; Mifepristone; conservative treatment Ectopic pregnancy is a common acute abdomen, one of Obstetrics and Gynecology, the incidence rate of about 1%, the major causes of death among pregnant women, of which the most common tubal pregnancy. Widely promoted in recent years, non-surgical treatment, of which more positive effect of methotrexate with mifepristone. In this paper, methotrexate and mifepristone treatment of non-ruptured tubal pregnancy in 36 cases achieved better results. 1 Data and methods 1.1 Case Selection In line with conservative treatment conditions: (1) no change in vital signs; (2) unruptured tubal pregnancy or abortion; (3) No internal bleeding or bleeding less, no short-term or lower abdominal pain lower abdominal pain; (4) No liver, kidney disease, No MTX and mifep